A Phase 3 interventional study of sitagliptin phosphate (+) metformin hydrochloride and Comparator: pioglitazone in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-06-09.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 29th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 74 in phase 3, and was the 33rd registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 78 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 23 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 517 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 42nd largest by enrollment of the 170 interventional ones that give a count, is one of 26 that started in 2008, is one of 86 in phase 3, and was the 32nd registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes
General Inclusion Criteria:
General Exclusion Criteria:
Sitagliptin phosphate (+) metformin hydrochloride
Drug: sitagliptin phosphate (+) metformin hydrochloride
pioglitazone
Drug: Comparator: pioglitazone
Drug pages: Sitagliptin · Metformin
sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an \~32 wk treatment period
Also known as: Janumet
pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an \~32-wk treatment period.
Also known as: pioglitazone
Change From Baseline in A1C at Week 32
A1C is measured as a percent. Thus this change from baseline reflects the Week 32 A1C percent minus the baseline A1C percent
Time frame: Baseline and Week 32
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 1
Change from baseline reflects the Week 1 FPG minus the baseline FPG. At Week 1, the dose was 50/500 mg b.i.d. for Sita/Met FDC and 30 mg q.d. for pioglitazone
Time frame: Baseline and Week 1
Change From Baseline in 2-hour Post-Meal Glucose (PMG) at Week 32
Change from baseline reflects the Week 32 2-hour PMG minus the baseline 2-hour PMG
Time frame: Baseline and Week 32
Change From Baseline in FPG at Week 32
Change from baseline reflects the Week 32 FPG minus the baseline FPG
Time frame: Baseline and Week 32
Percent of Participants With A1C <7.0% at Week 32
Time frame: Week 32
First Patient In: 19-Mar-2008 Last Patient Last Visit: 23-Oct-2009 Seventy-four medical clinics worldwide (19 sites in the United States, 31 in Eastern Europe, and 24 in the rest of the world).
| Milestone | Sitagliptin/Metformin Fixed-Dose Combination | Pioglitazone |
|---|---|---|
| Started | 261 | 256 |
| Completed | 210 | 204 |
| Not completed | 51 | 52 |
| Withdrew: Adverse event | 11 | 12 |
| Withdrew: Lack of efficacy | 0 | 3 |
| Withdrew: Lost to follow-up | 10 | 6 |
| Withdrew: Physician decision | 4 | 5 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Protocol violation | 4 | 2 |
| Withdrew: Withdrawal by subject | 10 | 9 |
| Withdrew: Protocol specific criteria | 11 | 15 |
A1C is measured as a percent. Thus this change from baseline reflects the Week 32 A1C percent minus the baseline A1C percent
| Percent of glycosylated hemoglobin (A1C) | Sitagliptin/Metformin Fixed-Dose Combination | Pioglitazone |
|---|---|---|
| Change From Baseline in A1C at Week 32 | -1.86 (-2.00 to -1.73) | -1.39 (-1.53 to -1.26) |
Change from baseline reflects the Week 1 FPG minus the baseline FPG. At Week 1, the dose was 50/500 mg b.i.d. for Sita/Met FDC and 30 mg q.d. for pioglitazone
| mg/dL | Sitagliptin/Metformin Fixed-Dose Combination | Pioglitazone |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 1 | -40.5 (-44.1 to -36.9) | -13.0 (-16.6 to -9.3) |
Change from baseline reflects the Week 32 2-hour PMG minus the baseline 2-hour PMG
| mg/dL | Sitagliptin/Metformin Fixed-Dose Combination | Pioglitazone |
|---|---|---|
| Change From Baseline in 2-hour Post-Meal Glucose (PMG) at Week 32 | -102.2 (-110.7 to -93.8) | -82.0 (-90.4 to -73.7) |
Change from baseline reflects the Week 32 FPG minus the baseline FPG
| mg/dL | Sitagliptin/Metformin Fixed-Dose Combination | Pioglitazone |
|---|---|---|
| Change From Baseline in FPG at Week 32 | -56.0 (-60.9 to -51.0) | -44.0 (-49.1 to -39.0) |
| Percent Participants | Sitagliptin/Metformin Fixed-Dose Combination | Pioglitazone |
|---|---|---|
| Percent of Participants With A1C <7.0% at Week 32 | 57.3 | 43.5 |
Collected over Week 0 through Week 32. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin/Metformin Fixed-Dose Combination | — | 11/261 (4.2%) | 94/261 (36%) |
| Pioglitazone | — | 8/256 (3.1%) | 68/256 (26.6%) |
| Event | Sitagliptin/Metformin Fixed-Dose Combination | Pioglitazone |
|---|---|---|
| CholelithiasisHepatobiliary disorders | 3/261 | 0/256 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/261 | 1/256 |
| PharyngitisInfections and infestations | 0/261 | 1/256 |
| PneumoniaInfections and infestations | 0/261 | 1/256 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/261 | 1/256 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/261 | 1/256 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/261 | 1/256 |
| Urine flow decreasedRenal and urinary disorders | 0/261 | 1/256 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/261 | 1/256 |
| Conjunctivitis allergicEye disorders | 1/261 | 0/256 |
| Event | Sitagliptin/Metformin Fixed-Dose Combination | Pioglitazone |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 40/261 | 11/256 |
| HypoglycaemiaMetabolism and nutrition disorders | 22/261 | 11/256 |
| HeadacheNervous system disorders | 20/261 | 7/256 |
| Oedema peripheralGeneral disorders | 3/261 | 18/256 |
| Upper respiratory tract infectionInfections and infestations | 13/261 | 17/256 |
| NasopharyngitisInfections and infestations | 10/261 | 16/256 |
| DyspepsiaGastrointestinal disorders | 13/261 | 2/256 |
| Age, Continuous(years) | Sitagliptin/Metformin Fixed-Dose Combination | Pioglitazone | Total |
|---|---|---|---|
| Mean | 52.4 ± 10.7 | 52.2 ± 11 | 52.3 ± 10.8 |
| Sex: Female, Male(Participants) | Sitagliptin/Metformin Fixed-Dose Combination | Pioglitazone | Total |
|---|---|---|---|
| Female | 118 | 122 | 240 |
| Male | 143 | 134 | 277 |
| Race/Ethnicity, Customized(participants) | Sitagliptin/Metformin Fixed-Dose Combination | Pioglitazone | Total |
|---|---|---|---|
| White | 168 | 167 | 335 |
| Black | 6 | 5 | 11 |
| American Indian | 2 | 0 | 2 |
| Asian | 58 | 55 | 113 |
| Multi-racial | 27 | 29 | 56 |
| Hemoglobin A1C (A1C)(Percent of glycosylated hemoglobin (A1C)) | Sitagliptin/Metformin Fixed-Dose Combination | Pioglitazone | Total |
|---|---|---|---|
| Mean | 9.0 ± 1.3 | 8.9 ± 1.3 | 8.9 ± 1.3 |
| Fasting Plasma Glucose (FPG)(mg/dL) | Sitagliptin/Metformin Fixed-Dose Combination | Pioglitazone | Total |
|---|---|---|---|
| Mean | 190.6 ± 53.4 | 188.9 ± 57.1 | 189.8 ± 55.2 |
| 2-Hour Post-Meal Glucose (2-HR PMG)(mg/dL) | Sitagliptin/Metformin Fixed-Dose Combination | Pioglitazone | Total |
|---|---|---|---|
| Mean | 273.7 ± 84.8 | 278.8 ± 86.4 | 276.2 ± 85.5 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Jan 2008 to primary completion in Oct 2009, 20 months.
Results were first posted in Oct 2010, 11 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sitagliptin · Metformin